What a drugmaker can learn from patients

Japanese pharmaceutical company Eisai innovates by prioritizing patient needs

From the research and development of a symptomatic treatment in the 1980’s, to its continued development of anti-amyloid-beta and anti-tau antibodies, Eisai has built its rich neurology pipeline during the past four decades. Even when faced with complexities and challenges that caused others to exit the effort, Eisai has never given up on developing therapeutic solutions for families living with AD and other neurogenerative diseases.